Cargando…
Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic peptide, survivin-2B80–88, a member of the inhibitor of apoptosis protein family, recognized by CD8+cytotoxic T lymphocytes (CTL). In a phase I clinical trial of survivin-2B80-88 vaccination for metastatic urothelial c...
Autores principales: | Tanaka, Toshiaki, Kitamura, Hiroshi, Inoue, Ryuta, Nishida, Sachiyo, Takahashi-Takaya, Akari, Kawami, Sachiyo, Torigoe, Toshihiko, Hirohashi, Yoshihiko, Tsukamoto, Taiji, Sato, Noriyuki, Masumori, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863714/ https://www.ncbi.nlm.nih.gov/pubmed/24363758 http://dx.doi.org/10.1155/2013/262967 |
Ejemplares similares
-
GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis
por: Inoue, Ryuta, et al.
Publicado: (2017) -
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer
por: Honma, Ichiya, et al.
Publicado: (2009) -
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients
por: Kobayashi, Jun-ichi, et al.
Publicado: (2009) -
Late Recurrence and Second Primary Malignancy among 139 Patients with Germ Cell Tumors: Long-term Outcome of the Disease in a Single-center Experience
por: Sato, Shunsuke, et al.
Publicado: (2010) -
Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)